Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

233
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
233

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic and redox pathway dysregulation in HIV-associated coronary endothelial dysfunction.

American journal of physiology. Heart and circulatory physiology·2026
Same author

Lipoprotein(a) and oxidized phospholipids are associated with myocardial inflammation after acute myocardial infarction.

Nature cardiovascular research·2026
Same author

Lipoprotein(a) is associated with coronary inflammation in people with HIV and undetectable HIV RNA.

European heart journal. Imaging methods and practice·2026
Same author

Addressing myocardial infarction in South-Asian populations: risk factors and machine learning approaches.

NPJ cardiovascular health·2026
Same author

Reassessing the First Step: Lessons From ES-BempedACS and the Era of Multi-Mechanism LDL-C Lowering.

Circulation·2026
Same author

Tailoring strategies for dyslipidemia management and atherosclerotic cardiovascular disease prevention in muscular dystrophy patients.

Journal of clinical lipidology·2026

Related Experiment Video

Updated: Jan 18, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.6K

Precision approach in apoA-I infusion trials: When CSL112 may actually work.

Vignesh Chidambaram1, Amudha Kumar2, Thorsten M Leucker3

  • 1Division of Cardiology, Department of Medicine, John H. Stroger Hospital of Cook County, Chicago, IL, USA (Dr Chidambaram).

Journal of Clinical Lipidology
|January 16, 2026
PubMed
Summary

Apolipoprotein A-I (apoA-I) infusion showed no overall cardiovascular benefit post-myocardial infarction. However, efficacy may depend on elevated LDL-C and inflammation, suggesting precision approaches for future trials.

Keywords:
Apolipoprotein A-ICholesterol effluxHDLInflammationLDL

More Related Videos

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

61.7K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.6K

Related Experiment Videos

Last Updated: Jan 18, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.6K
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

61.7K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.6K

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Pharmacology

Background:

  • The ApoA-I Event Reducing in Ischemic Syndromes II trial found CSL112 (apoA-I infusion) ineffective for major cardiovascular events in all post-myocardial infarction patients.
  • Exploratory analyses indicated potential benefits in specific patient subgroups with high LDL-C and systemic inflammation.

Purpose of the Study:

  • To investigate the critical role of elevated LDL-C and systemic inflammation in CSL112 efficacy.
  • To propose a precision-stratification framework for future apoA-I infusion trials based on ATP-binding cassette transporter A1 (ABCA1) biology.
  • To explore patient selection strategies and combination therapies for impaired ABCA1 function.

Main Methods:

  • Integrating ABCA1 transporter biology with subgroup trial data.
  • Analyzing the interplay of lipid burden and inflammation on ABCA1 function.
  • Evaluating ex vivo efflux assays and molecular transporter profiling for patient selection.

Main Results:

  • CSL112 efficacy appears contingent on the co-occurrence of elevated LDL-C and systemic inflammation.
  • Statin therapy may downregulate ABCA1 transporter function.
  • Future trials may benefit from stratifying patients based on ABCA1 transporter status.

Conclusions:

  • Precision medicine approaches are crucial for optimizing apoA-I infusion therapy.
  • Targeting ABCA1 transporter function, potentially with combination therapies, could enhance cardiovascular outcomes.
  • Further research into patient stratification and combination therapies is warranted.